Cite
Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations.
MLA
Gollins, Simon, et al. “Preoperative Chemoradiation with Capecitabine, Irinotecan and Cetuximab in Rectal Cancer: Significance of Pre-Treatment and Post-Resection RAS Mutations.” British Journal of Cancer, vol. 117, no. 9, Oct. 2017, pp. 1286–94. EBSCOhost, https://doi.org/10.1038/bjc.2017.294.
APA
Gollins, S., West, N., Sebag-Montefiore, D., Myint, A. S., Saunders, M., Susnerwala, S., Quirke, P., Essapen, S., Samuel, L., Sizer, B., Worlding, J., Southward, K., Hemmings, G., Tinkler-Hundal, E., Taylor, M., Bottomley, D., Chambers, P., Lawrie, E., Lopes, A., & Beare, S. (2017). Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations. British Journal of Cancer, 117(9), 1286–1294. https://doi.org/10.1038/bjc.2017.294
Chicago
Gollins, Simon, Nick West, David Sebag-Montefiore, Arthur Sun Myint, Mark Saunders, Shabbir Susnerwala, Phil Quirke, et al. 2017. “Preoperative Chemoradiation with Capecitabine, Irinotecan and Cetuximab in Rectal Cancer: Significance of Pre-Treatment and Post-Resection RAS Mutations.” British Journal of Cancer 117 (9): 1286–94. doi:10.1038/bjc.2017.294.